SHANGHAI, China, January 9, 2024 - MSD announced that it has received approval from the State Drug Administration of China (SDA) for a new two-dose vaccination program (0, June to December) for females aged 9 to 14 years for its nine-valent human papillomavirus vaccine (brewer's yeast) (trade name: Gardasil®9). This approval means that Gardasil®9 will be added to the previous three-dose vaccination program for women aged 9~45 years old, providing more economical and convenient health protection for more women of the appropriate age group, and helping them to stay away from cervical cancer and cervical lesions associated with HPV infection.

Gardasil®9 is indicated for the prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58; cervical intraepithelial neoplasia (CIN grades 1/2/3) and adenocarcinoma in situ (AIS) of the cervix caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 causing persistent infections.

Cervical cancer is one of the most common gynecological malignancies. 2023 ICO/IARC Report on HPV and Related Diseases in China shows that in 2020, cervical cancer will be the third most prevalent female tumor in terms of both incidence and mortality among women aged 15-44 years in China. In China, about 98% of cervical cancers are caused by high-risk HPV, and persistent high-risk HPV infection may lead to cervical, anal, vaginal, vulvar, penile and oropharyngeal cancers, etc. HPV 16 and 18 are high-risk HPVs that are widely prevalent globally, but with variations in China, and an epidemiological study summarizing HPV infections among 1.7 million women in China showed that An epidemiologic study summarizing HPV infections in 1.7 million Chinese women showed that the high-risk HPV types most likely to be infected in Chinese women are HPV 16, 52, and 58, respectively.

https://mp.weixin.qq.com/s/zVKkJDu3AK60tMFzn2y2NQ